Donor CAR T Cells Added to Transplant to Prevent Relapse in adults with B-ALL
Official title: Donor Derived CD19/CD22 CAR T Cells as Concurrent Therapy Against Relapse in Adults with B-ALL
Funded at Stanford University · NIH-11400088 · Data updated 2026-11-12
A new approach combines donor CAR-T cells targeting CD19 and CD22 with a stem cell transplant to lower relapse risk in adults with B-ALL.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project start | May 1, 1997 |
| Project end | August 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $472,379 |
| NIH project number | 5P01CA049605-35 |
| Project ID | NIH-11400088 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults (21+) with B-ALL undergoing allo-HCT who are eligible for donor-derived CAR T cells and regulatory T cell–based grafts.
✕Less likely to help
Patients not undergoing allogeneic transplant or those with contraindications to donor CAR T cells or regulatory T cell therapy may not benefit.
What this research studies
This project explores giving donor-derived CAR T cells after an allogeneic stem cell transplant to reduce relapse and balance the fight against leukemia with reduced graft-versus-host disease. The plan includes using regulatory T cells with the transplant and a consolidative infusion of donor CAR19/22 T cells. Researchers will look at safety, feasibility, and correlative biological data from patients treated in a phase I setting, alongside supportive preclinical work. If successful, this strategy could offer a more durable remission for adults with B-ALL who are undergoing transplant.
Why it matters
Potential benefit: If successful, patients may experience lower relapse rates and longer remissions after transplant.
How similar studies have gone: Prior autologous CD19/CD22 CAR T approaches showed remissions but with relapse; donor-derived CAR T cells after allo-HCT are promising but evidence is still early.
Where this research is happening
-
Stanford University
Stanford, United States Active
Researchers
- Principal investigator: Miklos, David B. — Stanford University
- Study coordinator: Miklos, David B.
Related research
Other NIH-funded projects on the same topics.
-
Metabolic drivers of B-ALL diversity and relapse risk
A study at Stanford will explore how diverse B-cell receptor rearrangements and their metabolism shape relapse risk in children and adults with B-ALL, with the goal of improving detection and treatment.
-
Donor CAR T cells targeting CD19 and CD22 to prevent relapse in adult B‑ALL
Adults with B‑cell acute lymphoblastic leukemia receive a donor stem‑cell transplant with regulatory T cells followed by donor CAR T cells that target CD19 and CD22 to try to lower the chance the leukemia comes back.
-
Social stress and smoking: why disadvantaged young adults struggle to quit
This grant looks at how daily social stress affects if and when disadvantaged young adults who smoke can quit and stay quit.
-
Learning from remission and relapse in lupus (SLE)
Researchers are studying people with systemic lupus erythematosus who are in long-term remission without steroids or immunosuppressants to understand their immune cells, brain function, and what might predict relapse.
-
Learning from Remission and Relapse in SLE
A program to study people with systemic lupus erythematosus who are in long-term remission to understand immune and brain signals that might predict relapse.
-
Alternative NF-kB activation after chemotherapy in ovarian cancer
This grant studies how ovarian cancer might come back after chemotherapy by looking at specific signaling pathways in cancer cells and the tumor environment.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.